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This clinical practice position statement, a product of the Fatty Liver Research Group of the Korean Diabetes Association, propos-
es recommendations for the diagnosis, progression and/or severity assessment, management, and follow-up of non-alcoholic fatty 
liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Patients with both T2DM and NAFLD have an increased 
risk of non-alcoholic steatohepatitis (NASH) and fibrosis and a higher risk of cardiovascular diseases and diabetic complications 
compared to those without NAFLD. With regards to the evaluation of patients with T2DM and NAFLD, ultrasonography-based 
stepwise approaches using noninvasive biomarker models such as fibrosis-4 or the NAFLD fibrosis score as well as imaging stud-
ies such as vibration-controlled transient elastography with controlled attenuation parameter or magnetic resonance imaging-
proton density fat fraction are recommended. After the diagnosis of NAFLD, the stage of fibrosis needs to be assessed appropri-
ately. For management, weight reduction achieved by lifestyle modification has proven beneficial and is recommended in combi-
nation with antidiabetic agent(s). Evidence that some antidiabetic agents improve NAFLD/NASH with fibrosis in patients with 
T2DM is emerging. However, there are currently no definite pharmacologic treatments for NAFLD in patients with T2DM. For 
specific cases, bariatric surgery may be an option if indicated.
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INTRODUCTION
This clinical practice position statement, a product of the Fatty 
Liver Research Group (FLRG) of the Korean Diabetes Associa-
tion (KDA), proposes recommendations for the diagnosis, 
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low-up of non-alcoholic fatty liver disease (NAFLD) in pa-
tients with type 2 diabetes mellitus (T2DM). The literature was 
retrieved by an extensive PubMed search up to April 2019. Af-
ter extensive reviews and discussions for the last 3 years by the 
research group, two sentinel reviews were published in Diabe-
tes and Metabolism Journal in 2019. The draft of the statement 
was presented and discussed in a session of the FLRG during 
the 32nd KDA scientific meeting in 2019. Then, the statement 
was further discussed, edited and updated until the final ac-
ceptance of the statement in the journal. Epidemiological evi-
dence suggests a strong bidirectional relationship between type 
2 diabetes mellitus (T2DM) and non-alcoholic fatty liver dis-
ease (NAFLD), including the development and severity of 
NAFLD, progression to non-alcoholic steatohepatitis (NASH), 
and advanced fibrosis, independent of liver enzymes [1]. Fur-
thermore, the coexistence of T2DM and NAFLD results in an 
unfavorable metabolic profile and an increasing cardiovascular 
(CV) risk [2-4]. Although steatosis can be defined by various 
clinically available diagnostic tools, it can be numerically and 
strictly defined by assessing liver fat: ≥5% of fat-containing he-
patocytes in histology; proton density fat fraction (PDFF) ≥5% 
on magnetic resonance imaging (MRI), or >5.5% on proton 
magnetic resonance spectroscopy (1H-MRS) [5,6]. The defini-
tive diagnosis of NASH requires a liver biopsy.
Among many treatments for NAFLD in patients with 
T2DM, weight reduction is the only approved option for 
NAFLD. However, it is not easy to maintain weight loss by only 
lifestyle modification strategies, so additional pharmacological 
options should be supported. To date, although many drugs 
have been investigated, pioglitazone could be the first-line 
therapy in patients with T2DM and NAFLD. Many drugs are 
currently being developed and investigated, and combination 
strategies will be introduced for the treatment of NAFLD and 
diabetes in the future. 
PREVALENCE OF NAFLD IN PATIENTS WITH 
T2DM
Keynotes
- The prevalence of NAFLD in patients with T2DM is more than two times 
higher than that in the normal population.
-NAFLD is a risk factor for T2DM.
NAFLD is the most common liver disorder, affecting 20% to 
40% of adults; the prevalence rates differ according to the diag-
nostic method, age, sex, and ethnicity [6-8]. In patients with 
T2DM, NAFLD prevalence ranges from 70% to 95%; the rate 
is extremely high, up to 98%, in patients with morbid obesity 
[8]. In the general Korean population, NAFLD prevalence 
ranges from 16.1% to 25.2% (Table 1) [9,10]. 
Half of patients with T2DM have NAFLD despite having nor-
mal alanine aminotransferase (ALT) levels [11,12]. Population 
based studies have reported the prevalence of NASH to be 
17.6% to 22%% in individuals with T2DM and 3.7% in nondia-
betic individuals [13]. Furthermore, the prevalence of NASH 
among biopsied patients with diabetes can be as high as 64.0%, 
whereas the prevalence of advanced fibrosis (≥F3) in patients 
with T2DM is approximately 10.4% [14]. The NAFLD preva-
lence in Asians is not lower than that in Caucasians. In a study 
involving Korean patients with T2DM who were subjected to 
ultrasonography (US) examination in a university-based diabe-
Table 1. The prevalence of NAFLD and NASH in patients with diabetes
Study Study population Diagnostic methods Categories Prevalence, %
Mohan et al. (2009) [16] In 132 Indian adults with diabetes US NAFLD 54.5
Kim et al. (2014) [17] In 4,437 Korean patients with T2DM US NAFLD 72.7
Targher et al. (2007) [18] In 2,839 Italian patients with T2DM US NAFLD 69.5
Portillo-Sanchez et al. (2015) [11] In 103 American patients with diabetes with 
normal plasma aminotransferases
1H-MRS NAFLD 50
Williams et al. (2011) [13] In 54 biopsied patients with diabetes Liver biopsy NASH 22
Hyysalo et al. (2014) [12] In 115 biopsied participants in in the Finnish 
population-based D2D-study
Liver biopsy NASH 17.6
Kim et al. (2014) [15] In 929 Korean patients with diabetes US NAFLD 63.3
US, ultrasonography; NAFLD, non-alcoholic fatty liver disease; 1H-MRS, proton magnetic resonance spectroscopy; T2DM, type 2 diabetes mel-
litus; NASH, non-alcoholic steatohepatitis.
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tes clinic, 63.3% of patients had NAFLD (Table 1) [11-13,15-18]. 
Furthermore, the risk of diabetes in subjects with NAFLD 
has been shown to be 2-fold higher than that in control sub-
jects, even after adjustment for various risk factors [19,20]. 
When obesity, insulin resistance, or hyperglycemia is com-
bined with NAFLD, T2DM risk is dramatically increased [2]. 
In line with these studies, the resolution of steatosis in patients 
with NAFLD decreases T2DM risk by 39% to 82% [21,22].
THE PROGRESSION OF NAFLD AND 
DIABETES
Keynotes
- Patients with T2DM and NAFLD have an increased risk of NASH and  
fibrosis. 
- Patients with both T2DM and NAFLD have a higher risk of CV diseases 
and diabetic complications compared to those without NAFLD.
Approximately 10% to 35% of subjects with normal liver his-
tology progress to steatosis, 12% to 44% of those with hepatic 
steatosis progress to steatohepatitis, and up to 15% of patients 
with NASH are known to progress to cirrhosis [23]. In patients 
with NAFLD, the prevalence of NASH is approximately 60% in 
biopsy-indicated patients and 29.9% in patients without such 
an indication [8]. Studies have shown that increasing age, dia-
betes, and hypertension are predictive clinical parameters for 
fibrosis [24,25].
NAFLD and NASH can progress to cirrhosis and liver failure 
in up to 15% of affected patients [26]. These patients are also at 
risk of developing hepatocellular carcinoma (HCC). Advanced 
age, high aspartate aminotransferase (AST) levels, thrombocy-
topenia (marker of progression of liver fibrosis), and diabetes 
were identified as risk factors for the development of HCC in 
Japanese patients with US-diagnosed NAFLD. Patients with 
NAFLD with advanced stages of fibrosis have a 7-fold higher 
risk of HCC compared to those without liver disease [27]. 
However, the cause of cirrhosis remains unclear in 30% of cas-
es, and most of these cases are now considered NAFLD-related 
[28]. Cryptogenic cirrhosis was reported to be an underlying 
disease in approximately 7% of HCC cases in Korea and Japan 
compared with 13% in the United States [28,29]. T2DM is also 
closely associated with progression to NASH, advanced fibro-
sis and the development of HCC [1,7].
NAFLD is a consequence but also a precursor of metabolic 
comorbidities, including diabetes, dyslipidemia, and hyperten-
sion, and thus, NAFLD increases CV events, and mortality 
even in the absence of these comorbidities [30]. Furthermore, 
hepatic fibrosis is a key predictor of liver-related outcomes and 
is also associated with all-cause and CV mortality as well as 
mortality due to cirrhosis, HCC, and infectious diseases in 
NAFLD patients [31,32]. Diabetes is an important factor af-
fecting all-cause and CV mortality in patients with NAFLD 
[31]. Thus, after the diagnosis of NAFLD, the stage of fibrosis 
needs to be assessed appropriately [31]. There is evidence that 
the presence of NAFLD in patients with T2DM is associated 
with increased risks of macrovascular and diabetic microvas-
cular complications as well as chronic kidney disease [2].
DIAGNOSIS OF NAFLD
Keynotes
- NAFLD can be diagnosed by a two-step process: (1) confirmation of he-
patic steatosis, either by imaging modalities or histology and (2) exclu-
sion of secondary causes of liver steatosis.
Routine screening for NAFLD in patients with T2DM is not 
currently recommended because of the unclear cost-effective-
ness and uncertainties with diagnostic testing and treatments 
[33]. In individuals with and without diabetes, three important 
processes should be used to diagnose and assess NAFLD: (1) 
determine the existence of hepatic steatosis, either by imaging 
or histology; (2) exclude secondary causes of liver steatosis; 
and (3) assess NAFLD severity by establishing the presence of 
moderate-to-severe fibrosis (fibrosis stage of at least F2) [2]. 
Before making the diagnosis of NAFLD, secondary causes of 
hepatic fat accumulation and significant alcohol consumption 
(≥21 drinks/week for men and ≥14 drinks/week for women) 
need to be excluded [5]. Alcohol consumption over a 2-year 
time frame needs to be surveyed in detail using validated ques-
tionnaires [5]. However, it is noteworthy that there is also a 
synergy between alcohol intake and obesity or genetic risk fac-
tors of NAFLD progression for any given level of alcohol intake 
[6]. Even in patients whose alcohol consumption level is low, 
meeting the diagnostic criteria of NAFLD, small amounts of 
alcohol intake may affect outcomes in NAFLD, which warrants 
further study [5,34]. After performing a history and examina-
tion, the next investigations are to establish whether the patient 
has NAFLD or another liver condition. 
A consensus regarding initial blood tests for NAFLD has not 
been reached among guidelines [33]. The decision on the ex-
tent of liver blood tests and interpretation of the results should 
be determined in a clinical context. In adults, initial screening 
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tests may include abdominal US, hepatitis B surface antigen, 
hepatitis C antibody (with follow-on polymerase chain reac-
tion if positive), anti-mitochondrial antibody, anti-smooth 
muscle antibody, antinuclear antibody, serum immunoglobu-
lins, and simultaneous serum ferritin and transferrin satura-
tion [33]. Although ALT levels have been shown to be the best 
single biochemical correlate of hepatic steatosis, liver enzyme 
levels can be normal, fluctuating, or elevated in patients with 
NAFLD [23]. There have been suggestions that the current ref-
erence intervals for ALT may be too high [35,36], and a recent 
guidance recommending an ALT of >30 U/L as being signifi-
cant in males and >25 U/L significant for females [37]. 
Noninvasive imaging studies to assess hepatic steatosis and 
hepatic fibrosis
Keynotes
- Despite its limited accuracy, US is a useful screening tool to detect hepatic 
steatosis with other possible structural abnormalities in patients who are 
suspected of having NAFLD.
- Vibration-controlled transient elastography (VCTE) with controlled at-
tenuation parameter (CAP) is a simple quantitative index to detect ste-
atosis in clinical practice, but CAP values should be carefully interpreted 
with patient factors such as obesity.
- As the MRI-PDFF is a highly reliable modality for detecting steatosis, 
comparable to liver biopsy, it is useful for sequent monitoring, such as in 
clinical trials.









accessibility Cost Specific comments
Hepatic steatosis
  US Specific sonographic 
findings
+ +++ + (bedside) + Cannot detect mild steatosis, observer 
dependency
  CT Liver HU <40 or liver 
HU-spleen HU <−10
++ +++ ++ ++ Radiation hazard
Diverse criteria for definition  
(liver/spleen ratio of HU, etc.)
Low sensitivity in mild steatosis
  MRI-PDFF ≥5% liver fat +++ +++ +++ +++ Optimal for clinical trials
  1H-MRS ≥5.6% liver fat +++ + +++ +++ Gold standard 
Sampling errors
Requires expertise/device
  CAP by VCTE ≥248–≥288 dB/m 
(variable cutoffs)
++ + + (bedside) + Not linear with a higher liver fat content
Results are affected by BMI, diabetes, 
etiology
XL probe for the obese
Hepatic fibrosis
  MRE Advanced fibrosis (F3) 
threshold >2.4–5.55 
kPa
+++ +++ +++ +++ Diverse cut-off points by type of  
modality (2D, 3D, etc.)
Most accurate but expensive
Failure risk in iron overload condition
  LSM by VCTE Diverse cutoffs (7.3–9.9 
kPa) for advanced fi-
brosis (F3)
++ + + (bedside) + Affected by BMI (failure risk)
XL probe for the obese
VCTE can measure CAP and LSM  
simultaneously
US, ultrasonography; CT, computed tomography; MRI-PDFF, magnetic resonance imaging-proton density fat fraction; 1H-MRS, proton mag-
netic resonance spectroscopy; CAP, controlled attenuation parameter; VCTE, vibration-controlled transient elastography; BMI, body mass in-
dex; MRE, magnetic resonance elastography; LSM, liver stiffness measurement.
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Currently, US, computed tomography (CT), MRI, 1H-MRS, 
and VCTE are available tools to measure NAFLD depending 
on the center or clinic (Table 2, Fig. 1).
Ultrasonography and computed tomography
US is the recommended first line screening method for pa-
tients with T2DM by the European NAFLD guidelines [34]. 
US has interobserver variability and limited sensitivity to de-
tect mild (<20%) steatosis [38], while optimum sensitivity for 
liver US was reported to be achieved at a liver fat content of 
≥12.5% (sensitivity of approximately 80% to 85%) [39,40]. 
Similar to US, CT has limited sensitivity to detect mild ste-
atosis (<30% liver fat). Radiation exposure is an additional 
drawback. Thus, CT scans cannot be recommended for the di-
agnosis of hepatic steatosis [2]. 
Vibration-controlled transient elastography 
VCTE measures the speed of a mechanically induced shear 
wave across the liver using pulse-echo ultrasonic acquisitions 
to obtain a liver stiffness measurement (LSM), as a marker of 
hepatic fibrosis, and ultrasonic attenuation through the liver to 
derive the CAP, as a marker of hepatic steatosis. VCTE is an 
easy-to-perform tool to obtain both LSM and CAP values us-
ing an M (3.5 MHz, at 2.5 to 6.5 cm-depth) or XL (2.5 MHz, at 
3.5 to 7.5 cm-depth) ultrasound probe. Although LSM and 
CAP values are relatively reliable and well-validated, these pa-
rameters are affected by various patient factors, especially body 
mass index which may lead to an overestimation [41,42]. With 
the availability of the XL probe, which has been proven for use 
in patients with morbid obesity, the failure rate of VCTE for 
obtaining the LSM and CAP values was reported to be less 
Exclude secondary causes
Fig. 1. Algorithm for non-alcoholic fatty liver disease (NAFLD) evaluation. CV, cardiovascular; NFS, NAFLD fibrosis score; BMI, 
body mass index; IFG, impaired fasting glucose; DM, diabetes mellitus; AST, aspartate aminotransferase; ALT, alanine aminotrans-
ferase; FIB-4, fibrosis-4; PLT, platelet; APRI, AST to platelet ratio index; ULN, upper limit of normal; VCTE, vibration-controlled 
transient elastography; ELF, enhanced liver fibrosis; MRE, magnetic resonance elastography. aHigher cutoffs for patients aged >65 
years, bVariable cutoffs have been suggested. Measured values are affected by body factors, cFurther validation is required.
Non-alcoholic fatty liver disease in type 2 diabetes mellitus
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than 5%, while the significant disagreement between the first 
and second readings for LSM and CAP when obtained back to 
back was 18% and 11%, respectively [43]. 
Magnetic resonance imaging-based techniques
MRI-PDFF can provide fast, quantitative, accurate, and gener-
alized hepatic fat measurements for the entire liver, thereby 
overcoming the heterogeneity of fat deposition [44,45], while 
magnetic resonance elastography (MRE) is a useful diagnostic 
tool for the differentiation of histologically determined ad-
vanced liver fibrosis from non-advanced fibrosis [46,47]. Addi-
tionally, LSM measured by MRE may reflect whole liver pa-
thology rather than that of a very small area. MRI-PDFF is be-
coming the gold standard for hepatic steatosis quantification 
[48]. MRI-PDFF or 1H-MRS can measure liver fat more pre-
cisely than biopsy [49,50]. In a secondary analysis of a clinical 
trial involving patients with biopsy-proven NASH, it was 
shown that histologic responders (≥2-point reduction in 
NAFLD activity score [NAS], without any worsening of fibrosis 
on liver biopsy) had a proportional reduction in the MRI-
PDFF of 29.3% from baseline which was statistically significant 
when compared with histologic nonresponders [51]. However, 
at the present time, magnetic resonance techniques cannot be 
used for the assessment of NASH resolution or the exact assess-
ment of fibrosis progression or improvement. Thus, these is-
sues need to be addressed when designing future clinical trials.
Liver biopsy
Liver biopsy provides an accurate diagnosis in approximately 
90% of patients with unexplained abnormalities revealed by 
liver function tests [52]. Noninvasive tools for fibrosis staging 
are not reliable for therapeutic or other decisions but may be 
helpful for excluding the probability of significant fibrosis and 
for predicting advanced fibrosis, thus guiding the decision to 
perform liver biopsy or not in a patient with NAFLD [53]. 
Further studies are required to determine whether an active 
NASH screening strategy in patients with T2DM and active 
therapy on the basis of the currently available evidence are 
cost-effective and beneficial for long-term CV and liver-related 
outcomes. Health care providers taking care of patients with 
diabetes are strongly encouraged to be vigilant for any signs 
and symptoms of chronic liver disease and, if indicated, further 
assessment of the stage of hepatic fibrosis should be conducted 
[54,55].
Further assessment after the diagnosis of hepatic steatosis
Keynotes
- Staged approaches are recommended to determine the extent of liver fi-
brosis in patients with NAFLD.
- To estimate hepatic fibrosis using nonimaging modalities, noninvasive 
biomarker models such as fibrosis-4 (FIB-4) or the NAFLD fibrosis score 
(NFS) are well-validated and widely used for screening high-risk patients.
- To assess liver fibrosis, VCTE is a point-of-care imaging device with 
moderate accuracy and high accessibility, while MRE has better accuracy 
performance, but it is not widely available.
The severity of hepatic fibrosis is the most powerful determi-
nant of long-term outcomes, including mortality [31]; thus, 
the assessment of fibrosis is essential to manage patients with 
NAFLD. Although quantitative noninvasive imaging assess-
ment of steatosis is feasible in the clinical setting, none of the 
current imaging technologies can reliably differentiate simple 
steatosis from NASH or detect its progression to early stage fi-
brosis [56]. Several prediction scores have been developed and 
validated to identify or exclude advanced fibrosis (≥F3). First-
line testing should use either FIB-4 or the NFS. As an alterna-
tive, the AST to platelet ratio index [APRI] may also be used. 
Those patients with indeterminate FIB-4 (1.3 to 2.67) or NFS 
scores (−1.455 to 0.676) require a second-line test in a context 
dependent manner: VCTE, serum enhanced liver fibrosis 
(ELF) score, or MRE. The ELF score is a surrogate index based 
on extracellular matrix panel consisting of plasma concentra-
tions of hyaluronic acid, tissue inhibitor of metalloproteinase 1, 
and procollagen type III amino-terminal peptide [57] Howev-
er, the ELF test seems to need further validation, even though 
European guidelines recommend the test [34]. Patients with 
high FIB-4 (>2.67) or NFS (>0.676) values should be consid-
ered for referral to a specialist clinic irrespective of second-line 
tests (Fig. 1) [33]. Thus, the use of these scores in combination 
with imaging studies seems to be more reasonable. The cyto-
keratin 18 fragment test did not outperform AST measure-
ment in discriminating NASH from simple steatosis [58]. 
By using VCTE, the threshold values of CAP (≥263 to 288 
dB/m) for steatosis and the LSM (≥8.6 to 9.6 kPa) for ad-
vanced fibrosis have been variably reported [39,48]. The very 
low values of the LSM (e.g., <5.6 or <6.5 kPa combined with a 
result from other noninvasive tests) suggest an exclusion of 
moderate fibrosis (Fig. 1) [59]. Although the threshold levels 
for the changes of MRI-PDFF to define improvement of ste-
atosis seem to be 25% to 30%, the cutoff value for percent 
change in MRE to define the improvement of fibrosis needs 
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further studies; it seems that more than a 20% difference is re-
quired to be confident [60].
Genetic variant study
Keynotes
- Genetic tests for the assessment of NAFLD are not officially recommend-
ed, but identifying the carriers of high-risk genetic variants may be help-
ful in some specific conditions.
Genetic factors are also important factors that determine sus-
ceptibility to the development and progression of NAFLD, con-
sidering that heritable factors account for approximately 50% of 
the interindividual differences in the prevalence of NASH with 
cirrhosis in a twin study [61]. Among several genetic risk fac-
tors, single-nucleotide polymorphisms (SNPs) in patatin-like 
phospholipase domain–containing 3 (PNPLA3) (rs738409 
c.444 C>G, p.I148M), transmembrane 6 superfamily, member 
2 (TM6SF2) (rs58542926 c.449 C>T, p.E167K), and membrane 
bound O-acyltransferase domain containing 7-transmembrane 
channel-like 4 (MBOAT7) (rs641738 C>T) have been relatively 
well validated to promote the development of NAFLD and its 
progression (i.e., cirrhosis, HCC, or both) [62-66].
PNPLA3 encodes adiponutrin, a triglyceride (TG) lipase that 
regulates both TG and retinoid metabolism. The PNPLA3 
I148M variant is resistant to proteasomal degradation by evad-
ing ubiquitylation and accumulates on lipid droplets, which in-
terferes with lipolysis and causes a change in phospholipid re-
modeling [67]. The PNPLA3 SNP rs738409 is strongly associat-
ed with hepatic steatosis, steatohepatitis, fibrosis, and HCC [66].
TM6SF2 is involved in very low-density lipoprotein (VLDL) se-
cretion from hepatocytes. The SNP rs58542926 C>T in TM6SF2 
results in a loss-of-function, inducing a higher liver TG content 
and lower circulating lipoproteins. As with PNPLA3, the TM6SF2 
minor (T) allele is associated with greater hepatic steatosis, more 
severe NASH and greater hepatic fibrosis/cirrhosis, but intrigu-
ingly, the more common major (C) allele is associated with the 
promotion of VLDL excretion, conferring an increased risk of 
dyslipidemia and cardiovascular disease (CAD) [65,68]. In line 
with this, in a large exome-wide association study of plasma 
lipids in more than 300,000 individuals, the PNPLA3 I148M 
and TM6SF2 E167K variants were strongly associated with he-
patic steatosis and progression to NASH, cirrhosis, and HCC, 
but also with increased risk of diabetes, lower blood TG, lower 
low-density lipoprotein cholesterol (LDL-C) concentrations, 
and protection from CAD [66]. 
The MBOAT7 rs641738 T allele is associated with reduced 
MBOAT7 protein expression and has been shown to be associ-
ated with an increase in the risk of steatosis and histologic liver 
damage in NAFLD (i.e., higher severity of necro-inflammation 
and fibrosis) independent of obesity [69]. The variant may also 
predispose patients to HCC in patients without cirrhosis 
[65,70]. The MBOAT7 gene encodes lysophosphatidylinositol 
(LPI) acyltransferase 1, known as LPIAT1 or MBOAT7, which 
selectively uses LPI and arachidonoyl-CoA to form 2-arachi-
donoyl phosphatidylinositol (PI) [71,72]. Consistent with this 
function, lipidome changes in the plasma and liver of patients 
with NAFLD have been reported: decreases in plasma levels of 
PI (36:4), PI (38:3), and PI (38:5) and decreases in hepatic con-
centrations of PI (36:4) and PI (38:3) in proportion to the num-
ber of MBOAT7 variant alleles [69,73]. LPIAT1 contributes to 
the regulation of free arachidonic acid in the cell through the 
remodeling of phospholipids [74]. MBOAT7 deficiency is thus 
predicted to increase free polyunsaturated fatty acids and their 
pro-inflammatory eicosanoid lipids [70,75].
Interestingly, in an Italian cohort study that evaluated the re-
lationship between HCC risk and the total number of risk al-
leles including PNPLA3 I148M, TM6SF2 E167K, and MBOAT7 
rs641738 T, there was a significant association between the 
number of risk alleles and HCC [70].
In addition, several protective variants have also been re-
ported [76]. In particular, SNPs (rs72613567, rs62305723, and 
rs6834314) in HSD17B13, a gene that encodes the hepatic lip-
id droplet protein 17β-hydroxysteroid dehydrogenase type 13, 
were reported to be associated with decreased inflammation, 
ballooning, and liver enzyme levels in patients with NAFLD 
[77,78]. Recently, HSD17B13 was identified as a lipid droplet 
enzyme retinol dehydrogenase, highlighting the importance 
of retinoid homeostasis in NAFLD and its progression [78]. 
The splice variant rs72613567 produces a truncated, nonfunc-
tional protein that was associated with lower odds of various 
liver diseases and HCC [77]. It was also found that the isoform 
encoded by the protective allele is catalytically defective against 
estradiol [77].
Nutritional factors are very important even when consider-
ing genetic factors, as adiposity has been shown to amplify the 
effect of the NAFLD risk alleles in PNPLA3, TM6SF2, and glu-
cokinase regulatory protein (GCKR) [79,80]. Currently, genetic 
tests are not officially recommended, but identifying carriers of 
high risk genetic variants may be helpful in some specific con-
ditions.
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TREATMENT OF NAFLD
Keynotes
- Management for patients with T2DM and NAFLD should be aimed at 
reducing the risk factors associated with their high CV risk as well as de-
creasing hepatic fat accumulation and delaying the progression of inflam-
mation and fibrosis.
- Lifestyle modification is the first step in the management for all patients 
with T2DM and NAFLD to improve NAFLD as well as hyperglycemia, 
dyslipidemia, and blood pressure levels.
Epidemiological evidence suggests a strong bidirectional rela-
tionship between T2DM and NAFLD. Furthermore, NAFLD 
resolution attenuates T2DM risk, but when obesity, insulin re-
sistance, or hyperglycemia is combined with NAFLD, the 
T2DM risk is significantly increased [4]. In a long-term follow-
up study of patients with NAFLD, diabetes and smoking, along 
with fibrosis, age, and absence of statin use, contributed to 
mortality, underscoring the need for a comprehensive ap-
proach to patient management [32]. Additionally, spontaneous 
regression of NASH and even NASH-related fibrosis has been 
observed in clinical trials and may be related to lifestyle modi-
fications and behavioral changes [81]. However, pharmacolog-
ical treatment is more powerful than lifestyle modification for 
glucose control. Moreover, lifestyle modification plus anti-dia-
betic drugs are likely to have a synergistic effect on reducing 
the risk factors associated with CV risk and decreasing hepatic 
fat accumulation in these patients, thereby delaying the pro-
gression of inflammation and fibrosis. Therefore, all patients 
with T2DM and NAFLD should be strongly encouraged to 




- Weight loss induced by either lifestyle modification or bariatric surgery 
improves glucometabolic profiles and reduces liver fat in subjects with 
T2DM. 
- Regarding lifestyle modification, specific diets rather than calorie restric-
tion or specific types of exercise protocols (aerobic or resistance) were not 
clearly defined for their efficacy at the present time.
It is well established that weight loss induced by either lifestyle 
modification or bariatric surgery in overweight or obese indi-
viduals with T2DM results in significant improvement or reso-
lution of T2DM and its comorbidities such as hypertension, 
and hyperlipidemia [3,83,84]. In addition, weight reduction 
has been associated with alleviated intrahepatic fat contents 
and aminotransferase levels [81]. Even relatively small amounts 
of weight loss can reduce liver fat and improve hepatic insulin 
resistance independent of any changes in insulin-stimulated 
peripheral glucose metabolism [85]. In adult populations with 
NAFLD, a systematic review that included a total of 23 studies 
evaluating the effect of lifestyle interventions, such as diet, 
physical activity, and/or exercise, on the hepatic indicators of 
steatosis, inflammation and fibrosis as well as glucose control/
insulin sensitivity showed that the reductions in liver fat and/
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or liver aminotransferase concentrations were strongly corre-
lated with weight loss [86]. However, it should be noted that 
sustainable maintenance of weight loss with lifestyle interven-
tions for long-term periods was achievable in only 3% to 6% of 
the subjects [9,15].
The magnitude of weight reduction 
Keynotes
- The improvement in histology is proportional to the magnitude of the 
weight loss, but this proportional trend might not be applicable to gluco-
metabolic profiles.
- A magnitude of weight loss in the range of approximately 5% to 7% may 
clearly decrease steatosis but approximately 8% to 10% weight reduction 
is needed to reverse steatohepatitis.
In adult populations with NAFLD, a greater degree of weight 
loss, induced by either lifestyle modifications or bariatric sur-
gical procedures, is associated with a greater improvement in 
histologic features [82]. Summarizing all current available re-
ports, it appears that a magnitude of weight loss in the range of 
approximately 5% to 7% may clearly decrease steatosis and the 
associated metabolic parameters, but 8% to 10% weight reduc-
tion is needed to reverse steatohepatitis [3,83,85-88]. Although 
a ≥7% weight loss also improved NAS, fibrosis was unchanged. 
Furthermore, the highest rates of NAS reduction, steatohepati-
tis resolution, and fibrosis regression occurred in patients with 
≥10% weight loss [89]. The threshold of 7% weight loss was 
achieved by <50% of patients, even with intensive multidisci-
plinary lifestyle intervention. 
Lifestyle modification 
Keynotes
- The weight reduction achievable by dietary program remains the corner-
stone of lifestyle modification for patients with T2DM and NAFLD. 
- Caloric restriction, rather than dietary macronutrient composition, has a 
greater role in preventing the development and progression of T2DM, in 
reducing hepatic steatosis and in delaying inflammation and fibrosis. 
- Exercise per se can reduce hepatic fat even in the absence of weight loss. 
Both aerobic and resistance exercise leading to a similar weight reduction 
are similarly effective in hepatic fat reduction in patients with T2DM. 
- Individually tailored approaches combining a mainly hypocaloric diet in 
conjunction with a progressive increase in aerobic exercise/resistance 
training are associated with the magnitude of the weight reduction.
Of the ways to achieve weight reduction, lifestyle modification 
that includes a programmed diet and exercise is an effective 
and sound treatment for all patients with NAFLD and NASH 
[34,82,90]. In addition, lifestyle modification improves hyper-
glycemia, atherogenic dyslipidemia, and blood pressure levels 
[91-93]. Of the lifestyle programs, however, weight reduction 
achievable by dietary programs or interventions remains the 
cornerstone of lifestyle modification for all patients with 
T2DM and NAFLD [34,82,90]. It seems that caloric restric-
tion, rather than dietary macronutrient composition, has a 
greater role in reducing hepatic fat and delaying the progres-
sion of inflammation and fibrosis in patients with NAFLD 
[81,83,85,86,94-96]. Regarding the macronutrient composi-
tion, comparable effects have been observed with equally hy-
pocaloric low-carbohydrate versus high-carbohydrate diets 
[97] and low-fat versus low-carbohydrate diets [98]. Exercise 
trials have reported an inconsistent amount of weight loss or 
changes in surrogate biomarkers achieved after exercise inter-
ventions, but the heterogeneities of the baseline characteristics 
of the study subjects and the exercise protocols must also be 
considered [3,99,100]. Even with these findings, physical activ-
ity, either aerobic or resistance type, should be strongly pro-
moted for the management of fatty liver in patients with 
T2DM because the benefits are not exclusively contingent 
upon weight loss [101]. It seems that, despite the unclear bene-
ficial roles of exercise on weight loss and hepatic fat reduction, 
exercise itself has been shown to improve liver enzymes and 
insulin resistance in all patients with diabetes with NAFLD 
and NASH [102,103]. A comprehensive approach with com-
bined dietary and exercise interventions has shown significant 
benefit on NAFLD, especially for long-term intervention peri-
ods. However, whether a combined lifestyle intervention has 
synergistic effects compared to the separate approaches of diet 
and exercise is unclear. A meta-analysis by Keating et al. [102] 
showed that a combined dietary and exercise intervention had 
no significant pooled effects size (ES) when compared to diet 
alone (ES: –0.05; 95% confidence interval, –0.38 to 0.27; P= 
0.76). However, another systematic review that included eigh-
teen studies to investigate whether a diet-plus-exercise inter-
vention for a minimum of 6 months was more effective for 
weight loss than a diet-only intervention among obese or over-
weight adults showed that a combined diet-plus-exercise inter-
vention provided greater long-term weight loss than a diet-on-
ly intervention [104]. Although the effects of lifestyle modifica-
tion in the absence of weight loss on NAFLD and NASH might 
not be clear, it is clear that lifestyle changes with either or both 
a hypocaloric diet and exercise reduce the risk of CV disease 
and the onset and progression of T2DM [34,82,105].
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Pharmacologic treatment
For patients with T2DM and NAFLD, however, pharmacologi-
cal treatment is more powerful than lifestyle modification for 
glucose control. Moreover, lifestyle modification plus anti-dia-
betic drugs are likely to offer synergistic benefits for reducing 
the risk factors associated with their high CV risk [3,91] as well 
as decreasing hepatic fat accumulation and delaying the pro-
gression of inflammation and fibrosis. Therefore, especially in 
patients with T2DM, all patients should adopt both lifestyle 
changes and anti-diabetic medication use [82].
Anti-diabetic agents
Keynotes
- Patients with T2DM and NAFLD should adopt both lifestyle changes and 
anti-diabetic medication use.
- There are no definite pharmacologic treatments for NAFLD in patients 
with T2DM.
- Metformin is not recommended for treating NAFLD in patients with 
T2DM.
- Currently, pioglitazone could be a 1st-line option to improve NASH in 
patients with T2DM with some improvement in fibrosis.
- Evidence that sodium-glucose cotransporter 2 (SGLT2) inhibitors im-
prove NAFLD/NASH with fibrosis in patients with T2DM is emerging. 
Although not generally recommended, these agents may be considered 
as an initial treatment option in specific conditions for the treatment of 
NAFLD in patients with T2DM.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have some evi-
dence of improving NAFLD/NASH with fibrosis, but these agents are not 
generally recommended for the treatment of NAFLD in patients with 
T2DM.
- Dipeptidyl peptidase-4 (DPP-4) inhibitors are not recommended for 
treating NAFLD in patients with T2DM.
1) Metformin
Studies on metformin use in NAFLD failed to show any im-
provement in liver histology in patients with NAFLD and 
NASH [106,107]. Thus, metformin is not recommended for 
treating NAFLD in patients with T2DM. However, T2DM is 
now considered an independent risk factor for HCC and met-
formin may have a protective role in HCC occurrence [108].
2) Thiazolidinediones
Pioglitazone, one of the thiazolidinediones, is a peroxisome 
proliferator-activated receptor (PPAR)-γ agonist with insulin-
sensitizing effects. An randomized controlled trial (RCT) eval-
uating the efficacy and safety of long-term pioglitazone (45 
mg/day) treatment in patients with biopsy-proven NASH and 
prediabetes or T2DM showed that compared with the placebo 
group, only patients with T2DM showed a significant resolu-
tion of NASH (60% vs. 16%) and reduction in fibrosis from 
baseline [109]. Currently available data from previous studies 
suggest that, although it may reduce fibrosis, the clinical effect 
of pioglitazone may come from the suppression of rapid fibro-
sis progression rather than from fibrosis regression by turning 
off the metabolic drivers of liver fibrosis in T2DM [109,110]. 
Pioglitazone could be a first-line therapy for patients with 
NASH and T2DM. However, pioglitazone should not be rou-
tinely used to treat NAFLD in patients with T2DM because of 
limited data and the common side effects of weight gain, fluid 
retention, and bone mass loss.
Lobeglitazone is currently being prescribed for T2DM in 
Korea. In a multicenter, prospective clinical trial, patients with 
T2DM and NAFLD treated with lobeglitazone (0.5 mg daily) 
for 24 weeks had improved liver enzymes and ameliorated he-
patic fat contents assessed by VCTE-CAP [111].
3) Sodium-glucose cotransporter 2 inhibitors
SGLT2 inhibitors, including dapagliflozin, canagliflozin, empa-
gliflozin, ipragliflozin, and luseogliflozin are being used in-
creasingly in the treatment of T2DM; they promote weight loss 
which is an attractive property for the treatment of patients 
with NAFLD. Although SGLT2 inhibitors are not yet generally 
recommended for the treatment of NAFLD in patients with 
T2DM, emerging data suggest that SGLT2 inhibitors reduce the 
risk of progression of NAFLD [112], as the following results 
have been reported: a decrease in hepatic fat content [113,114]; 
a decrease in AST and ALT [114,115]; a decrease in the mea-
sures of fibrosis, such as the FIB-4 index [115,116], the fibrosis 
index calculated from hyaluronic acid and type IV collagen 7S 
[116], and VCTE-measured LSM [117]; an improvement in he-
patic insulin sensitivity [114]; and histology [118]. Well-de-
signed RCTs are needed to elucidate whether SGLT2 inhibitors 
should be used as the first-line drug choice in patients with 
NAFLD/NASH with T2DM. In the meantime, these agents 
may be considered as an initial option to treat NAFLD in pa-
tients with T2DM and specific cardio-renal conditions [119].
4) Glucagon-like peptide-1 receptor agonists
GLP-1 RAs, including exenatide, lixisenatide and liraglutide, 
are promising candidates for the treatment of NAFLD and 
NASH because they can reduce weight and enhance insulin 
action. However, GLP-1 RAs are not generally recommended 
for the treatment of NAFLD in patients with T2DM because of 
the limited data to date [112]. In a well-performed clinical trial 
in patients with biopsy-proven NASH, liraglutide (1.8 mg dai-
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ly) treatment for 48 weeks was associated with greater resolu-
tion of steatohepatitis and less progression of fibrosis [120].
5) Dipeptidyl peptidase-4 inhibitors
DPP-4 inhibitors including sitagliptin, vildagliptin, linagliptin, 
saxagliptin, gemigliptin, alogliptin, teneligliptin, and anagliptin 
are commonly used in patients with T2DM, but there are few 
studies about the efficacy of DPP-4 inhibitors in patients with 
T2DM and NAFLD; they are not yet believed to have a benefi-
cial effect on NAFLD. Only vildagliptin showed a clinically sig-
nificant decrease in hepatic TG levels measured by MRI-PDFF 
(27% with vildagliptin, from 7.3%±1.0% [baseline] to 5.3%± 
0.9% [endpoint]), unrelated to changes in body weight, during 
6 months of therapy in patients with T2DM and NAFLD [121]. 
Mixed results have been reported for sitagliptin. A pilot clinical 
study demonstrated that sitagliptin could improve hepatocyte 
ballooning and liver enzymes in patients with T2DM and 
NASH after 1 year of treatment [122]. However, many other 
studies have failed to show an effect of sitagliptin treatment on 
liver fat content or liver stiffness [123,124].
Non-antidiabetic agents
Keynotes
- Vitamin E is not recommended to treat NAFLD in patients with T2DM. 
- Lipid-lowering agents such as statins, ezetimibe, fibrates, niacin, omega-3 
polyunsaturated fatty acids, and colesevelam did not improve hepatic ste-
atosis in patients with NAFLD.
- Ursodeoxycholic acid (UDCA) and pentoxifylline are not recommended 
for the treatment of NAFLD or NASH.
- Obeticholic acid may improve NASH without progression of fibrosis in 
patients with T2DM and NASH. Further studies are required to prove its 
efficacy and long-term effects as well as its adverse effects.
1) Vitamin E
Vitamin E is an antioxidant that prevents liver injury by block-
ing intrinsic apoptotic pathways and protecting against oxida-
tive stress. Vitamin E improves liver histology in nondiabetic 
adults with biopsy-proven NASH [125], but is not recom-
mended in patients with diabetes because of a lack of evidence 
[5,82]. In addition, there are some concerns that long-term use 
of vitamin E may be associated with increased all-cause mor-
tality, an increased incidence of hemorrhagic stroke, and an in-
creased risk of prostate cancer.
2) Lipid-lowering agents
Although statins are beneficial in the management of dyslipid-
emia and high CV risk as well as in reducing the risk of HCC 
and mortality, especially in patients with diabetes, lipid-lower-
ing agents such as statins, ezetimibe, fibrates, niacin, omega-3 
polyunsaturated fatty acids, and colesevelam did not improve 
hepatic steatosis in patients with NAFLD [5,82,126]. There was 
also no evidence for the use of one of these agents for the treat-
ment of NAFLD in patients with T2DM.
3) Ursodeoxycholic acid
UDCA, a naturally occurring bile acid, reduced oxidative 
stress and had antiapoptotic properties. Although several stud-
ies reported that UDCA improved liver enzymes and hepatic 
steatosis in patients with NAFLD [127,128], both conventional 
(13 to 15 mg/kg daily) and high (23 to 28 mg/kg daily) doses of 
UDCA failed to induce histologic improvement in patients 
with NASH [129,130].
4) Pentoxifylline
Pentoxifylline inhibits a number of proinflammatory cytokines 
including tumor necrosis factor-α. Although pentoxifylline 
(400 mg three times a day) improved the histological features 
of NASH in 55 adults with biopsy-confirmed NASH, only 
9.1% of participants had T2DM [131]; another study reported 
no histological improvement in 30 patients, so larger studies 
are needed to establish the role of pentoxifylline in the man-
agement of patients with NASH and T2DM [132].
5) Obeticholic acid
Obeticholic acid is a natural agonist of the farnesoid X receptor 
and decreases insulin resistance and hepatic steatosis in animal 
models. Obeticholic acid (25 mg daily) treatment for 72 weeks, 
where 52.7% of patients had T2DM, improved liver histology 
in patients with NASH but increased LDL-C levels and caused 
pruritus [133]. Further studies are needed to clarify the long-
term benefit and safety of obeticholic acid in patients with 
T2DM and NAFLD.
6) Carnitine
Carnitine is a modulator of mitochondrial free fatty acid trans-
port and oxidation and has antioxidative activity in hepato-
cytes [98]. In patients with NASH, L-carnitine treatment (1 g 
daily) for 24 weeks improved liver enzymes and histological 
manifestations [134]. Treatment with the carnitine-orotate 
complex (824 mg, three times daily) for 12 weeks in patients 
with T2DM and NAFLD improved serum ALT and improved 
hepatic steatosis as assessed by CT in 78 patients [135].
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7) Elafibranor
Elafibranor is a dual agonist of PPAR-α and PPAR-δ and im-
proves insulin resistance in liver and peripheral tissue. In a 
phase 2b trial, elafibranor treatment (120 mg daily) for 52 
weeks tended to induce resolution of NASH without fibrosis 
progression despite some methodological limitations. The pre-
defined endpoint was not met in the intention to treat popula-
tion and 39.1% of study participants had T2DM [136]. 
8) Cenicriviroc 
Cenicriviroc, a dual antagonist of the C-C chemokine receptor 
types 2 and 5, has potent anti-inflammatory and antifibrotic 
activity in animal models. In a phase 2b study, in which half of 
subjects had T2DM and two-thirds had metabolic syndrome, 
cenicriviroc treatment (150 mg daily) for 1 year achieved im-
provement in fibrosis and no worsening of steatohepatitis 
compared with placebo [137]. 
9) Anti-obesity drugs
Because weight reduction is a key component for the treatment 
of NAFLD, anti-obesity drugs can be potential candidates. 
However, few studies have investigated the efficacy of anti-
obesity drugs for the treatment of NAFLD. Orlistat (120 mg 
three times daily for 6 months), an inhibitor of fat absorption, 
showed improved steatosis assessed by US and confirmed by 
liver biopsy in patients with NAFLD [138]. Another study 
evaluated the effect of orlistat on NAFLD in patients who re-
ceived a 1,400 kcal/day diet plus vitamin E (800 IU) daily. Orli-
stat (120 mg three times a day) did not enhance weight loss or 
improve liver enzymes and histopathology in fifty overweight 
subjects (10% of subjects had T2DM) [139]. 
Bariatric surgery 
Keynotes
- In addition to its effects on body weight and metabolic profiles, bariatric 
surgery can decrease long-term mortality related to diabetes, CV diseas-
es, and cancers.
- Bariatric surgery can be considered in obese patients with NAFLD and 
T2DM to resolve NASH and improve fibrosis.
Bariatric surgery has been accepted as a treatment option in 
obese patients with T2DM who do not achieve durable weight 
loss and improvement in comorbidities (including hyperglyce-
mia) with nonsurgical methods [119]. A meta-analysis showed 
that the majority of patients undergoing bariatric surgery ap-
pear to improve or completely resolve the histopathological 
features of steatosis, inflammation, and ballooning. Fibrosis 
also improved by a weighted mean decrease of 11.9% in the in-
cidence of fibrosis [140]. Another recent meta-analysis includ-
ing 3,093 biopsies also reported the resolution of steatosis in 
66% of patients, inflammation in 50%, ballooning degenera-
tion in 76%, and fibrosis in 40% [141]. With regard to proce-
dure selection, there is still a lack of data on which method, i.e., 
sleeve gastrectomy or Roux-en Y gastric bypass, is more effec-
tive. However, considering the safety of the surgery itself, 
sleeve gastrectomy is recommended in patients with NASH 
cirrhosis [82,142,143].
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